MK-677 (ibutamoren) is an oral compound that acts on ghrelin receptors to raise growth hormone and IGF-1 throughout the day. It is taken by mouth, not injected. It is a research compound and is not FDA-approved.

Tesamorelin is a synthetic copy of the hormone your brain uses to signal GH production. It is injected daily and is FDA-approved specifically to reduce deep belly fat in adults with HIV-associated lipodystrophy. It is sold as Egrifta.

MK-677 vs Tesamorelin: Oral Pill or Daily Injection?

Q: What is the main difference between MK-677 and tesamorelin?

The main differences are route of administration and GH pattern. MK-677 is taken orally and raises GH broadly all day. Tesamorelin is injected and produces a more targeted GH pulse. Tesamorelin also has FDA-approval and clinical trial data for visceral fat reduction that MK-677 does not have.

Q: Does MK-677 cause water retention?

Water retention is one of the most commonly reported effects of MK-677, particularly at the start of a protocol. It is related to the broad GH and IGF-1 increase. The effect varies by person and dose [verify: source].

Q: Can you stack MK-677 and tesamorelin?

Some researchers do combine them because they work through different receptor types. MK-677 acts on ghrelin receptors and tesamorelin acts on GHRH receptors. However, there is limited human data on the combination, and the overlap in GH stimulation may not add meaningfully for most people [verify: source].

Built by medical professionals, gym rats, and experienced biohackers

MK-677 vs tesamorelin is a choice between a convenient oral pill and a targeted injectable with clinical data. MK-677 raises GH and IGF-1 broadly all day. Tesamorelin drives a more focused GH pulse and has clinical trial results for belly fat reduction.

Quick Answer
MK-677 (ibutamoren) is for people who want an oral option that raises GH and IGF-1 around the clock, without injections. Tesamorelin is for people who want a targeted GH pulse, and specifically for those with clinically relevant visceral fat (deep belly fat). Verdict: if you want oral convenience and broad GH support, MK-677; if you want targeted visceral fat data and do not mind injections, tesamorelin.

What Is MK-677 (Ibutamoren)?

MK-677, also called ibutamoren, is a small molecule that binds to ghrelin receptors. Ghrelin receptors are the same receptors the hunger hormone uses. When MK-677 binds there, it signals the pituitary gland to release growth hormone.

Unlike most GH-related research compounds, MK-677 is taken by mouth. No injection needed. It raises both GH and IGF-1 (a downstream hormone that tracks GH activity) throughout the day. It produces a broad, sustained rise rather than a single timed pulse .

Common effects reported include water retention and increased appetite, especially early in a protocol. It is not FDA-approved and is used as a research compound.

What Is Tesamorelin?

Tesamorelin is a synthetic copy of a hormone your brain naturally makes. That hormone is called growth hormone releasing hormone (GHRH). GHRH tells the pituitary gland to produce GH. Tesamorelin mimics it closely.

It is injected under the skin once a day. It drives a GH pulse that follows a more natural rhythm than the sustained elevation from MK-677.

Tesamorelin is FDA-approved as Egrifta. Its approved use is reducing deep belly fat (visceral adipose tissue) in adults with HIV-associated lipodystrophy. That condition causes abnormal fat buildup in the abdomen . Off-label use for general body composition is not approved and has limited data.

How Do They Differ?

The two most important differences are route of delivery and GH pattern. MK-677 is oral and raises GH broadly all day. Tesamorelin is injected and raises GH in a more targeted pulse. Clinical evidence separates them further. Tesamorelin has completed Phase 3 human trials for visceral fat. MK-677 has some human data, but long-term results remain limited .

Mechanism. MK-677 binds to ghrelin receptors to trigger GH release. Tesamorelin binds to GHRH receptors, a completely different entry point, to do the same. Both raise GH but through different pathways.

Primary use. MK-677 is studied for GH and IGF-1 support, muscle preservation, and sleep quality. Tesamorelin's clinical trials focused specifically on reducing visceral fat in its approved population.

Typical research doses. MK-677: 10 to 25 mg oral once daily . Tesamorelin: 2 mg subcutaneous once daily .

Onset. MK-677 begins raising GH within an hour of a dose and keeps GH levels raised for most of the day. Tesamorelin produces a GH pulse peaking around 30 to 60 minutes after injection, then clearing .

Evidence level. Tesamorelin has completed human clinical trials showing significant visceral fat reduction in its studied population . MK-677 has some human trial data, including studies on muscle mass and IGF-1. But long-term safety data are limited . Both carry honest uncertainty about outcomes outside the studied groups.

Patterns in a GH protocol tend to emerge over weeks, not days. DoseVault is built for logging doses, timing, and personal notes in one structured place. That makes it easier to spot what is actually working.

MK-677 vs Tesamorelin: Side-by-Side Comparison

Feature	MK-677 (Ibutamoren)	Tesamorelin
Route	Oral	Subcutaneous injection
Receptor targeted	Ghrelin receptor	GHRH receptor
GH pattern	Broad, sustained elevation all day	Single daily pulse
IGF-1 effect	Significant increase	Moderate increase
FDA approval	No	Yes (HIV-related lipodystrophy)
Typical research dose	10 to 25 mg once daily	2 mg once daily
Water retention	Common, especially early	Less commonly reported
Appetite increase	Yes, often significant	Minimal
Human trial data	Some; long-term data limited	Phase 3 trials completed
Best studied for	IGF-1 elevation, muscle preservation	Visceral fat reduction

Can You Stack MK-677 and Tesamorelin?

Some researchers do combine these two. MK-677 uses ghrelin receptors and tesamorelin uses GHRH receptors. They do not directly compete at the receptor level. This is similar in principle to combining a GHRP and a GHRH analog.

That said, there is limited human data on this specific combination . The overlap in GH stimulation may produce diminishing returns for most goals. Both compounds raise GH through their own paths. Adding the second may not produce meaningfully more benefit than either alone.

This is a topic where honest tracking of your own response matters more than general assumptions.

Frequently Asked Questions

What is MK-677?
MK-677 (ibutamoren) is an oral compound that binds to ghrelin receptors. It raises GH and IGF-1 throughout the day. It is a research compound, not FDA-approved.

What is tesamorelin?
Tesamorelin is an injectable GHRH analog that mimics the brain's natural GH-release signal. It is FDA-approved to reduce deep belly fat in adults with HIV-associated lipodystrophy. Sold as Egrifta.

What is the main difference between MK-677 and tesamorelin?
MK-677 is oral and raises GH broadly all day. Tesamorelin is injected and produces a targeted daily GH pulse. Tesamorelin also has clinical trial data for visceral fat that MK-677 does not match.

Does MK-677 cause water retention?
Yes, water retention is one of the most common effects reported, particularly early in a protocol. It is related to the broad GH and IGF-1 increase .

Can you stack MK-677 and tesamorelin?
Some researchers do because they use different receptor types. But limited human data exists on the combination. The added benefit over using either one alone is not yet clear .

Which Do People Pick, and When?

This is general guidance, not personalized medical advice. Talk to a licensed clinician before starting any protocol.

Choose MK-677 if:
- You want GH and IGF-1 support without daily injections
- You are comfortable with possible water retention and increased appetite early on
- You want a broad-spectrum GH boost rather than a targeted fat-loss protocol

Choose tesamorelin if:
- Reducing visceral fat is a specific goal and you have clinical support
- You want a compound with completed Phase 3 human trial data
- You prefer a targeted daily GH pulse over an all-day sustained elevation

Consider both if:
- A clinician is overseeing your protocol and sees a reason to combine them
- You want both GHRH receptor and ghrelin receptor activation in the same plan

This page is for educational purposes only. It is not medical advice. Nothing here should be used to diagnose, treat, cure, or prevent any condition. MK-677 is not FDA-approved. Tesamorelin is a prescription drug with a specific FDA-approved indication. Consult a qualified healthcare provider before starting any peptide or research compound protocol.

Built by medical professionals, gym rats, and experienced biohackers

Tracking a GH protocol week by week? DoseVault keeps your dose log, timing, and notes all in one structured place.